SOUTH SAN FRANCISCO, Calif., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today
announced that Eric Bjerkholt, Chief Financial Officer of Sunesis, will present at the Dawson James Securities 2nd
Annual Small Cap Growth Stock Conference on Thursday, October 20th at 9:30 AM Eastern Time at the Wyndham Grand Hotel in
Jupiter, Florida.
A live webcast of the presentation will be available on the Sunesis website at http://ir.sunesis.com.
A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of
the Sunesis website for two weeks.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the
potential treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization
committed to improving the lives of people with cancer. Currently, the company is focused on pursuing regulatory approval in Europe
for its lead product candidate, vosaroxin, for the treatment of relapsed or refractory acute myeloid leukemia in patients aged 60
and older, as well as advancing its novel kinase-inhibitor pipeline, which includes its proprietary non-covalent BTK-inhibitor,
SNS-062.
For additional information on Sunesis, please visit http://www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717
